INT241803

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 2.41
Pain Relevance 0.30

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GBA) hydrolase activity, acting on glycosyl bonds (GBA) cell death (GBA)
carbohydrate metabolic process (GBA) lipid metabolic process (GBA)
Anatomy Link Frequency
lateral 1
GBA (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 14 81.84 Quite High
magnetoencephalography 5 74.56 Quite High
Neuropathic pain 1 50.32 Quite High
peripheral neuropathy 13 37.84 Quite Low
chemokine 12 5.00 Very Low Very Low Very Low
corticosteroid 6 5.00 Very Low Very Low Very Low
cytokine 5 5.00 Very Low Very Low Very Low
Central nervous system 4 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Fibrosarcoma 1 98.96 Very High Very High Very High
Gauchers Disease 148 98.34 Very High Very High Very High
Cancer 82 96.72 Very High Very High Very High
Adverse Drug Reaction 4 91.64 High High
Tinnitus 47 88.00 High High
Diffuse Large B-cell Lymphoma 112 83.64 Quite High
Pain 11 81.84 Quite High
Arrhythmia Under Development 2 75.96 Quite High
Dystocia 2 72.24 Quite High
Death 8 71.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The first of these, velaglucerase-alfa (VPRIV®), was generated by a rival company, originally Transkaryotic Therapies, now taken over by Shire Human Genetic Therapies (Dublin, Ireland).39 This agent is generated by gene activation of the endogenous human glucocerebrosidase gene in an immortalized human fibrosarcoma cell line.
Positive_regulation (activation) of glucocerebrosidase gene associated with fibrosarcoma
1) Confidence 0.70 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC3010821 Disease Relevance 0.24 Pain Relevance 0
As a result, GABAa mediated lateral inhibition is reduced, inducing a surrounding coupled gamma band activity (GBA) known as the “edge effect” [9], [11].
Positive_regulation (inducing) of GBA in lateral
2) Confidence 0.39 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2754613 Disease Relevance 0.72 Pain Relevance 0.24
The efficacy of miglustat in Gaucher disease type I probably results from both a decrease in the biosynthesis of GlcCer and an increase in the activity of glucocerebrosidase.


Positive_regulation (increase) of glucocerebrosidase associated with gauchers disease
3) Confidence 0.35 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.32 Pain Relevance 0
Miglustat is an oral medication that inhibits glucosylceremide synthase (substrate reduction therapy) and may partially increase glucocerebrosidase enzyme activity (chaperone mediated therapy).
Positive_regulation (increase) of glucocerebrosidase enzyme
4) Confidence 0.35 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.36 Pain Relevance 0.06
One hundred forty-nine of 163 DLBCLs could then be classified into GCB group (pattern A), activated GCB group (pattern B), and activated non-GCB group (pattern C) according to the expression of CD10, BCL6, MUM1, and CD138.
Positive_regulation (activated) of GCB
5) Confidence 0.04 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.48 Pain Relevance 0
Compared with cases with pattern A, those with patterns B (activated GCB group) and C (activated non-GCB group) more often presented with more aggressive tumors and a shorter survival time.
Positive_regulation (activated) of GCB associated with cancer
6) Confidence 0.04 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 0.29 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox